Skip to content

A Randomized Trial of Lenient Versus Strict Arm Instruction Post Cardiac Device Surgery

A Randomized Trial of Lenient Versus Strict Arm Instruction Post Cardiac Device Surgery - LENIENT

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04915261
Acronym
LENIENT
Enrollment
6300
Registered
2021-06-07
Start date
2021-08-19
Completion date
2030-08-01
Last updated
2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Op Complication

Keywords

Cardiac, Implantable, Electronic, Device, Arm, Restriction, Post-operative, infection, dislodgement, hematoma, DVT

Brief summary

The purpose and objectives of this study is to investigate whether reducing the existing arm restrictions on patients who receive Cardiac Implantable Electronic Devices (CIED) will result in an improved patient experience post operatively and reduce complication rates. There are multiple and varied arm restriction instructions given to patients receiving CIED's with limited universally accepted protocols or advice on restrictions for patients following surgery. Restrictions such as arm immobilization, showering and weight lifting, in addition to contradictory advice between various hospitals and physicians, can negatively affect patient quality of life and increase patient anxiety with no current evidence for benefit. A cluster cross over randomized trial has been designed to test the comparative effectiveness of lenient vs strict arm restrictions for all patients receiving implantable devices. Instructions within both arms of this study are considered within reasonable practice in Canada. All arm restriction instructions and parameters will be embedded within EPIC, nurses will teach the restriction in addition they will be provide to the patients via printed EPIC discharge summaries. Further links will be embedded in the After Visit Summary (AFS) printouts and my Chart for patients in EPIC. These instructions will be changed every 8 months, as per the crossover design of the trial. Additionally, both arms will utilize interactive voice recognition (IVR) to provide patients with further reminders and instruction on arm restrictions. All patients are given standard of care instructions for follow up and complication assessment through the investigators' device clinic and 24/7 on call nursing program.

Detailed description

The purpose and objectives of this study is to investigate whether reducing the existing restrictions on patients post CIED will result in an improved patient experience post operatively and reduce complication rates. Results from this study will create standardized, postoperative arm restriction recommendations more uniform between various hospitals. Hypothesis: The investigators hypothesize that outcomes of the post CIED implanted patients given lenient arm restriction will be non-inferior to those with prolonged arm restriction at reducing a combined primary endpoint of lead dislodgement, device infection, clinically significant pocket hematoma, upper limb DVT and frozen shoulder. Clinical relevance: The investigators anticipate that patients with minimal (lenient) arm restriction will have similar postoperative complication rates compared to the prolonged arm restriction. Should this hypothesis be proven, this will greatly improve patient quality of life post CIED with less stringent restrictions.

Interventions

BEHAVIORALLenient Arm Restriction

The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.

BEHAVIORALStrict Arm Restriction

The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.

Sponsors

Ottawa Heart Institute Research Corporation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

The trial is a single centre non-inferiority cluster crossover trial. Arm restriction protocol will cross over every 8 months with a one month run-in then 7 months of data collection.

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* all patients undergoing device surgery which includes implantation of at least one new endovascular lead

Exclusion criteria

* Standalone CIED generator replacement * Subcutaneous implantable cardioverter defibrillators * Leadless endocardial pacemakers * Temporary permanent pacemakers

Design outcomes

Primary

MeasureTime frameDescription
A composite of 1) Lead dislodgement 2) Frozen shoulder 3) Upper arm venous thrombosis 4) Clinically significant hematoma formation1 yearDefinitions of each component of primary outcome: 1. Lead dislodgement; dislodgment requiring surgical repair and dislodgement not occurring in the immediate post-op period (i.e., before the randomized intervention begins). Immediate post-op period is defined as from pocket closure to dislodgement suspected on first post- operative CXR (which is done 2-4hrs post-op). 2. Frozen shoulder in this study is defined as: Nursing or physician note mention of chronologically related (to index surgery) patient complaint of new or markedly worsened shoulder pain and/or restricted and stiffness of active and passive range of motion. 3. Upper arm venous thrombosis. 4. Clinically significant hematoma is defined as done in BRUISE CONTROL 2 trial: a hematoma that required re-operation and/or resulted in prolongation of hospitalization and/or required interruption of oral anticoagulation.

Secondary

MeasureTime frameDescription
Rate of hematoma1 year1\. Rate of hematoma (# of clinically significant hematoma / total number of procedures performed for each arm)
Rate of lead dislodgement1 year2\. Rate of lead dislodgement (# of lead dislodgements / total number of new leads placed in each arm) separate by type of lead (RA vs. RV vs. LV)
Rate of frozen shoulder1 year3\. Rate of frozen shoulder (# of frozen shoulders / total number of procedures performed for each arm)

Countries

Canada

Contacts

CONTACTTammy Knight
tknight@ottawaheart.ca613.696.7000
CONTACTMehrdad Golian
mgolian@ottawaheart.ca613.696.7271
PRINCIPAL_INVESTIGATORDavid Birnie

Ottawa Heart Institute Research Corporation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026